SCHEMBL5865619

SCHEMBL5865619

CS(=O)(=O)c1ccc(C(=C(Cl)Cl)c2ccc(Br)cc2)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 1/20 0.41
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
AKR1C3 P42330 1/20 0.36
HSD11B1 P28845 1/20 0.36
MAPT P10636 2/20 0.35
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
PIK3CD O00329 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5865564 0.88 MAPT (0.43) CCR2CA12CA1CA2CA9
SCHEMBL5865629 0.88 MAPK1 (0.53) CCR2CA12CA1CA2CA9
SCHEMBL5865698 0.87 CCR2 (0.39) CCR2CA12CA1CA2CA9
SCHEMBL5865566 0.84 MAPT (0.39) CCR2CA12CA1CA2CA9
SCHEMBL5865539 0.79 MAPK1 (0.50) CCR2CYP3A4TSHRMAPK1ATM
SCHEMBL29430629 0.77 HSD11B1 (0.48) CCR2CA1CA2CA9TSHR
SCHEMBL1581780 0.77 HSD11B1 (0.48) CCR2CA1CA2CA9TSHR
SCHEMBL5865494 0.77 TSHR (0.50) CCR2CYP3A4TSHRMAPK1ATM
SCHEMBL28669838 0.76 TSHR (0.57) TSHRMAPK1L3MBTL1MAPTLMNA
SCHEMBL5865511 0.76 L3MBTL1 (0.53) CA1CA2CYP3A4TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7091248-B2 Treatment of adrenocortical hypersecretion and tumor growth BRANDT INGVAR 2006-08-15 US disclosed
US-20040242705-A1 Novel treatment of adrenocortical hypersecretion and tumour growth BRANDT INGVAR (SE) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242705-A1 Novel treatment of adrenocortical hypersecretion and tumour growth NR3C2, NR5A1, NR3C1 CCR2 385/4885CA12 604/4885CA1 811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.